Akari Therapeutics, Plc

NasdaqCM:AKTX Stock Report

Market Cap: US$15.3m

Akari Therapeutics Future Growth

Future criteria checks 0/6

Akari Therapeutics's earnings are forecast to decline at 17.7% per annum. EPS is expected to grow by 43.3% per annum.

Key information

-17.7%

Earnings growth rate

43.27%

EPS growth rate

Biotechs earnings growth24.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated22 Apr 2026

Recent future growth updates

Recent updates

Seeking Alpha • Sep 27

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics press release (NASDAQ:AKTX): Q2 GAAP EPS of $0.00. As of June 30, 2022, the Company had cash of approximately $8.2 million, compared to cash of approximately $9.4 million as of December 31, 2021.
Analysis Article • Sep 20

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 28

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics (NASDAQ:AKTX) announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration. GA is a chronic progressive degeneration of the macula, which occurs during late-stage dAMD and can lead to irreversible vision loss. The result showed that the half-life within the eye of intravitreally injected early generation PAS-nomacopan (also referred to as PAS600 nomacopan) in a standard ophthalmic pre-clinical model can be accurately predicted, the company said.
Seeking Alpha • Jul 20

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics press release (NASDAQ:AKTX): Q1 GAAP EPS of $0.00. At March 31, 2022, the Company had cash of approximately $16.7 million, compared to cash of approximately $9.4 million at December 31, 2021.
Seeking Alpha • Jul 07

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics (NASDAQ:AKTX) on Thursday said a patient had completed a course of treatment with its inhibitor nomacopan in its phase 3 part A trial in kids with hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). HSCT-TMA is a complication that can happen following a stem cell transplant procedure which can lead to tissue hypoxia, blood clots and progressive organ damage and death. AKTX said one of the three patients with severe HSCT-TMA in the trial completed more than 60 days of treatment with nomacopan and was subsequently discharged from the hospital. Another patient died due to multi-organ failure that was unrelated to the treatment with nomacopan. Dosing has started in the third patient. Nomacopan had previously been granted orphan drug and fast track designations by the U.S. FDA for pediatric HSCT-TMA. U.S.-listed shares of AKTX gained 12.6% to $1.07 in early trading.
Analysis Article • Dec 31

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 15

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. By way of example, Akari Therapeutics...
Analysis Article • Jan 21

Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?

If you want to know who really controls Akari Therapeutics, Plc ( NASDAQ:AKTX ), then you'll have to look at the makeup...
Analysis Article • Dec 17

Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Earnings and Revenue Growth Forecasts

NasdaqCM:AKTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-29N/AN/A2
12/31/2027N/A-20N/AN/A2
12/31/2026N/A-15N/AN/A2
3/31/2026N/A-28-11-11N/A
12/31/2025N/A-17-11-11N/A
9/30/2025N/A-16-10-10N/A
6/30/2025N/A-12-9-9N/A
3/31/2025N/A-18-11-11N/A
12/31/2024N/A-20-13-13N/A
9/30/2024N/A-20-15-15N/A
6/30/2024N/A-20-16-16N/A
3/31/2024N/A-17-16-16N/A
12/31/2023N/A-10-16-16N/A
9/30/2023N/A-9-16-16N/A
6/30/2023N/A-10-17-17N/A
3/31/2023N/A-12-21-21N/A
12/31/2022N/A-18-22-22N/A
9/30/2022N/A-20-23-23N/A
6/30/2022N/A-18-20-20N/A
3/31/2022N/A-17-16-16N/A
12/31/2021N/A-17-19-19N/A
9/30/2021N/A-18-18-18N/A
6/30/2021N/A-16-17-17N/A
3/31/2021N/A-19-17-17N/A
12/31/2020N/A-17-17-17N/A
9/30/2020N/A-18-16-16N/A
6/30/2020N/A-21-20-20N/A
3/31/2020N/A-18-21-21N/A
12/31/2019N/A-17N/A-13N/A
9/30/2019N/A-13N/A-14N/A
6/30/2019N/A-14N/A-14N/A
3/31/2019N/A-18N/A-18N/A
12/31/2018N/A-20N/A-23N/A
9/30/2018N/A-25N/A-27N/A
6/30/2018N/A-32N/A-30N/A
3/31/2018N/A-24N/A-27N/A
12/31/2017N/A-35N/A-32N/A
9/30/2017N/A-32N/A-30N/A
6/30/2017N/A-22N/A-25N/A
3/31/2017N/A-28N/A-26N/A
12/31/2016N/A-18N/A-25N/A
9/30/2016N/A-3N/A-25N/A
6/30/2016N/A-52N/A-15N/A
3/31/2016N/A-47N/A-10N/A
12/31/2015N/A-45N/A-5N/A
9/30/2015N/A-53N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AKTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: AKTX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AKTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 01:12
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akari Therapeutics, Plc is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Sean LeeH.C. Wainwright & Co.